Extending follow-up visits in people with HIV (PWH) receiving bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) therapy: an expert opinion
Year: 2025
Type: article
Abstract: generation integrase inhibitors (INSTIs)-based three-drug regimens (3DR) are considered. Properties like intrinsic potency, genetic barrier, forgiveness, tolerability and safety make such regimens well suitable for less frequent immunovirological monitoring. The case of the single-tablet regimen consisting of Bictegravir/Emtricitabine/Tenofovir alafenamide (BIC/FTC/TAF) is unique, as in a single pill with a total net weight of 275 mg we actually find all the necessary ingredients to ensure the success of such initiative. Such powerful option looks as the most promising treatment to successfully increase the time between consultations and monitoring up to 9 or 12 months and thus providing the resulting advantages.
Source: Infezioni in Medicina
DOI: 10.53854/liim-3303-3
Authors: Giovanni Di Perri, Stefano Bonora
Institution: University of Turin
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4414020202